Clobazam
Epilepsies, Myoclonic
Epilepsies, Partial
Lennox Gastaut Syndrome
Seizures

Clobazam

Clobazam was synthesized in the 1960s with the primary goal of providing greater efficacy with fewer benzodiazepine-related side effects. FDA indications include adjunctive treatment of seizures associated with Lennox Gastaut syndrome in patients two years or older. Non-FDA-approved indications include adjunctive therapy for seizures seen with Dravet syndrome, adjunctive therapy for refractory status epilepticus, adjunctive therapy of refractory focal epilepsy, catamenial epilepsy, and anxiety. This activity reviews indications, mechanism of action, administration, contraindications, monitoring, and toxicity associated with clobazam and the role of the interprofessional team in caring for patients with conditions that indicate therapy with clobazam.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.